New research from the University of Michigan highlights the benefits of an RNA-based gene fusion assay added to standard myeloid next-generation sequencing (NGS) for detecting critical mutations in acute myeloid leukemia (AML). The study identified 89 gene fusions in over 600 AML cases, with 23 being cryptic and undetectable by traditional methods. By improving diagnostic accuracy and treatment selection, this technique could significantly enhance care for AML patients. These findings were presented at the Association for Molecular Pathology annual meeting.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.